MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients

MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients

20 April 2015

Melanoma Institute Australia and its key affiliate, Crown Princess Mary Cancer Centre Westmead were the highest recruiting centre worldwide for the study into the immunotherapies pembrolizumab versus ipilimumab, in advanced melanoma, with the findings published in the New England Journal of Medicine, the leading medical journal in the world.

The study found that the anti–PD-1 antibody pembrolizumab (trade name KEYTRUDA®) prolonged survival, and had less high-grade toxicity, compared with ipilimumab (trade name YERVOY®) in patients with advanced melanoma, that is, melanoma that has spread to distant parts of the body.

Associate Professor Georgina Long from Melanoma Institute Australia and University of Sydney said, “Here at MIA and Westmead we have been undertaking clinical trials with immunotherapy treatment using anti-PD-1 drugs for over three years, and these findings are the final piece of data that show the anti–PD-1 antibody pembrolizumab is better than current treatments for patients with advanced melanoma.”

The immune checkpoint inhibitor, ipilimumab, is one of the standard treatments for patients with advanced melanoma. The latest findings show that pembrolizumab, which inhibits the programmed death receptor 1 (PD-1) immune checkpoint on immune T cells, has antitumor activity: that is, it reduces the size of the tumours in patients with advanced melanoma in approximately 70% of patients, with deep reduction in over 30%, and prolongs survival compared with ipilimumab.

This clinical trial using pembrolizumab (KEYTRUDA®) recorded a 1 year survival rate of 74%, whilst those who received ipilimumab (YERVOY®) had a 1 year survival rate of 58%. Five years ago, only 30-35% of patients with advanced melanoma survived 1-year.

“These results are world-first, where two effective immunotherapies are directly compared, and we significantly improve outcomes for patients even further. This is great news for Australia, which has the highest incidence of melanoma in the world, and an Australian dies from this disease every 6 hours” said Assoc Prof Georgina Long. “This is evidence which will be considered by bodies around the world, including the Australian Government, to make these drugs accessible to all melanoma patients".

Research Co-Director of Melanoma Institute Australia and Macquarie University Professor Rick Kefford claims, “this breakthrough is probably the most important development in the treatment of this disease ever, and a landmark in terms of cancer treatment in general.”

Others Australian centres involved in this trial include: Newcastle Melanoma Unit, NSW; The Austin Hospital, VIC; Sir Charles Gardiner Hospital, WA; Princes Alexandra Hospital, QLD; Sydney Cancer Centre, RPAH, NSW.

 

World Health Organisation launches 4th edition of Classification of Skin Tumours
31 Aug 2018

World Health Organisation launches 4th edition of Classification of Skin Tumours

The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.

Professor John Thompson awarded prestigious 2018 RPA Foundation Research Medal
31 Aug 2018

Professor John Thompson awarded prestigious 2018 RPA Foundation Research Medal

Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.

Support PBS listing for pembrolizumab
23 Aug 2018

Support PBS listing for pembrolizumab

Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.

World Congress on Cancers of the Skin 2018
17 Aug 2018

World Congress on Cancers of the Skin 2018

The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.

Melanoma Institute Australia welcomes new CEO Matthew Browne
09 Aug 2018

Melanoma Institute Australia welcomes new CEO Matthew Browne

Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).

Melanoma in Practice: Nurse Conference
26 Jul 2018

Melanoma in Practice: Nurse Conference

It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’. 

Reducing the risk of melanoma in young adults
19 Jul 2018

Reducing the risk of melanoma in young adults

A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.

Melanoma Institute Australia launches free e-learning education portal
20 Jun 2018

Melanoma Institute Australia launches free e-learning education portal

Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.

David Day and a lifetime of missed moments
08 Jun 2018

David Day and a lifetime of missed moments

When David lost his life last year, he was 33, with three daughters under six.

Australian melanoma experts share latest breakthroughs with world's best oncologists
06 Jun 2018

Australian melanoma experts share latest breakthroughs with world's best oncologists

ASCO 2018 brings together the world's best in oncology from around the world. 

ASCO 2018 – the important role of clinical trials
06 Jun 2018

ASCO 2018 – the important role of clinical trials

Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.

MIA Scoops Awards at the International Academy of Pathology
04 Jun 2018

MIA Scoops Awards at the International Academy of Pathology

Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology. 

Updated Clinical Guidelines for Melanoma
25 May 2018

Updated Clinical Guidelines for Melanoma

Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.

Melanoma and Marital Status: A Study
11 May 2018

Melanoma and Marital Status: A Study

An American study has discovered a link between early detection and marital status in melanoma diagnosis. 

A weekend in Paris talking all things pathology...
02 May 2018

A weekend in Paris talking all things pathology...

An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.

Our own 'Australian Story'
30 Apr 2018

Our own 'Australian Story'

Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts. 

Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
27 Apr 2018

Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma

For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.

The inspiring story of Emma Betts premieres on Australian Story
16 Apr 2018

The inspiring story of Emma Betts premieres on Australian Story

'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma. 

Toyota helps tackle Australia's national cancer - melanoma
09 Apr 2018

Toyota helps tackle Australia's national cancer - melanoma

Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.

Tackling the Kokoda Trail for melanoma
06 Apr 2018

Tackling the Kokoda Trail for melanoma

Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.